Indaptus Therapeutics is trading 7.97% down at $1.27, primarily amid biotech-sector weakness and profit-taking after the prior session’s sharp advance.
- Shares rose 46.81% to $1.38 on August 20.
- No major company-specific announcement was identified on August 21; the August 17 resale prospectus was previously disclosed and covers existing shares, not a new issuance.
- Confidence is medium because company-specific coverage is limited.